Organon was a pharmaceutical company headquartered in
Oss,
Netherlands. In November 2007,
Schering-Plough Corporation, based in
New Jersey, USA, acquired Organon, active pharmaceutical ingredient producer
Diosynth (separate from Organon until 2004), and its veterinary pharmaceutical sister company
Intervet from
Akzo Nobel. In November 2009, Schering-Plough merged with
Merck & Co. under the name Merck & Co., known as Merck Sharp & Dohme or MSD outside the United States and Canada. Organon deals in the following core therapeutic fields:
reproductive medicine,
contraception,
psychiatry,
HRT and
anesthesia. Organon sells to international markets. In Oct. 16, 2014 USA government charged this drug manufacturer due to improper financial incentives (kicksbacks) to nursing homes for market-shares discounts to encourage the use of Remeron and also for misrepresentation of drug prices. Organon paid 622,350 in restitution for Federal Anti-Kickback Statute.